+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Algernon Pharmaceuticals

AGNPFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.057000

0.00509.62%

At close: -

$0.182000

0.13219.30%

After Hours: Apr 3, 4:00 PM EDT

Algernon Pharmaceuticals (AGNPF) Forecast

News

Earnings Algernon Pharmaceuticals (AGNPF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Algernon Pharmaceuticals (OTC:AGNPF) Stock

Algernon Pharmaceuticals Stock (OTC: AGNPF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 17, 2024

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Lara Goldstein

Wednesday, April 03, 2024

DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Lara Goldstein

Monday, August 14, 2023

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Lara Goldstein

Tuesday, August 08, 2023

DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
Vuk Zdinjak

Monday, June 05, 2023

DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Lara Goldstein

Tuesday, April 04, 2023

How To Finance A Psychedelics Business? Learn From These Four Companies
Lara Goldstein
Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
Lara Goldstein

Tuesday, March 07, 2023

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Lara Goldstein

Friday, March 03, 2023

Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
The Dales Report

Thursday, March 02, 2023

Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
Lara Goldstein

Tuesday, February 28, 2023

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Lara Goldstein

Tuesday, February 21, 2023

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Lara Goldstein
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
Lara Goldstein

Thursday, February 16, 2023

Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
Lara Goldstein

Wednesday, January 18, 2023

A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Lara Goldstein

Tuesday, January 03, 2023

Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
Lara Goldstein

Thursday, December 15, 2022

EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Lara Goldstein

Tuesday, November 22, 2022

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein

Wednesday, November 16, 2022

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Lara Goldstein

Monday, October 24, 2022

Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Lara Goldstein

Monday, September 12, 2022

A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Lara Goldstein

Thursday, September 08, 2022

Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Lara Goldstein

Tuesday, August 23, 2022

Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Lara Goldstein

Monday, July 18, 2022

Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Vandana Singh

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Monday, September 13, 2021

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Natan Ponieman

Tuesday, August 03, 2021

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Natan Ponieman

Monday, June 21, 2021

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman

Tuesday, April 06, 2021

Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
Natan Ponieman

Saturday, February 06, 2021

Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization
Natan Ponieman

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved